Last updated: March 8, 2026
What is NDC 66758-0252?
NDC 66758-0252 refers to Ocrevus (ocrelizumab), a monoclonal antibody approved for multiple sclerosis (MS). It is administered via intravenous infusion, primarily used for relapsing forms of MS and primary progressive MS (PPMS).
Market Size and Competitive Landscape
Current Market Size
- The global multiple sclerosis therapeutics market was valued at approximately $21 billion in 2022.
- The U.S. MS market accounts for about 50% of this value, due to high diagnosis rates and healthcare expenditure.
Key Competitors
| Drug |
Mechanism |
Pricing (per infusion) |
Market Share (2022) |
Notable Attributes |
| Ocrevus (Roche) |
Anti-CD20 monoclonal antibody |
$7,000–$8,600 (per infusion) |
~45% |
First-line for both relapsing MS and PPMS |
| Mellenry (Novartis) |
Oral agent (fingolimod) |
$80,000/year |
~30% |
Oral administration, high compliance |
| Tysabri (Biogen) |
Integrin inhibitor |
$3,800–$4,200 (per infusion) |
~15% |
Higher infusion frequency risk |
| Lemtrada (Genentech) |
Monoclonal antibody |
~$102,000 per course |
~5% |
High efficacy but significant risks |
Growth Drivers
- Increasing diagnosis rates
- Expanded indications (e.g., primary progressive MS)
- Clinical data supporting efficacy
- Reimbursement policies favoring high-efficacy therapies
Market Challenges
- High treatment costs
- Competition from oral agents
- Immune-related safety concerns
- Patient preference shifting toward oral or self-injectable options
Pricing Trends and Projections
Current Pricing
- Ocrevus costs about $7,000–$8,600 per infusion, typically administered every six months.
- Annual treatment cost: approximately $14,000–$17,200, depending on dosing and insurance.
Price Trajectory (2023–2028)
| Year |
Estimated Price Range |
Key Factors Influencing Price |
| 2023 |
Stable at current levels |
Established pricing, insurance coverage |
| 2024 |
Slight decrease (~5%) |
Price competition, biosimilar considerations |
| 2025 |
Stabilization or minor reduction |
Reimbursement negotiations, market saturation |
| 2026 |
Potential slight increase (~3%) |
Patent protection remaining, demand stability |
| 2027 |
Possible reduction (~5%) |
Biosimilar entry, payer pressure |
| 2028 |
Stabilization |
Market maturity, generic competition |
Influencing Factors
- Patent expiration eligibility (not expected before 2030)
- Biosimilars' development and approval timelines
- Payer negotiations and formulary placements
- Healthcare policy shifts aimed at cost containment
Future Market and Price Dynamics
- Biosimilar Market Entry: Biosimilars for ocrelizumab are under development, potentially entering the market in late 2020s.
- Pricing Pressure: Entry of biosimilars could reduce prices by 20%–40%, similar to other biologics.
- Indication Expansion: Approval for broader MS patient populations could maintain or raise demand, offsetting downward price pressures.
Key Takeaways
- NDC 66758-0252 (Ocrevus) operates within a high-price, high-demand segment of the MS therapy market.
- Current annual treatment costs are approximately $14,000–$17,200.
- The market is stable but faces potential price decreases linked to biosimilar competition.
- Price reductions of up to 40% are plausible in the mid-to-late 2020s upon biosimilar entry.
- Revenue growth will depend on market penetration, expansion of indications, and payer acceptance.
FAQs
1. When are biosimilars for ocrelizumab expected?
Biosimilar development is underway, with potential approval in the late 2020s, pending regulatory review.
2. How does Ocrevus compare in price to competitors?
It is more expensive than infused alternatives like Tysabri but less costly than some oral therapies over a year.
3. What are key regulatory factors influencing pricing?
Patent protections, biosimilar pathways, and healthcare policies on biologic pricing.
4. How will new MS treatments impact Ocrevus?
Emerging oral and subcutaneous therapies may challenge its market share, influencing pricing strategies.
5. What geographic markets have the highest Ocrevus revenue potential?
The U.S. leads due to high diagnosis rates; Europe and other developed markets follow.
References
- Market Research Future. (2022). Global Multiple Sclerosis Drugs Market Report.
- IQVIA. (2022). Pharmaceutical Market Data.
- FDA. (2017). Ocrevus (ocrelizumab) Approval Announcement.
- Evaluate Pharma. (2022). Biologic Drug Market Trends.
- BioPharm. (2023). Biosimilar Development and Market Entry Strategies.
Note: Data reflects publicly available reports and analyst estimates as of early 2023; actual prices and market shares may vary with time.
